Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 24th Preview)
-
Gilead front-loads $1.675B for Ouro... reshapes Galapagos role
Gilead Sciences agreed to acquire Ouro Medicines in a deal that pays roughly $1.675 billion upfront and up to $500 million in milestones, adding OM336 (gamgertamig), a BCMAxCD3 T‑cell engager, to its inflammation and cell‑therapy portfolio. Gilead said early trials show rapid, deep B‑cell depletion and granted Fast Track and Orphan designations from the FDA. The company expects registrational studies to start in 2027 and is in talks for Galapagos to absorb Ouro’s operating assets and staff, with Galapagos to lead development and Gilead retaining worldwide commercialization rights outside China. T‑cell engagers (TCEs) recruit T cells to target disease‑causing cells; regulatory designations accelerate development and can change commercialization timelines.
-
Novartis buys Synnovation’s PI3Kα program — $2B upfront
Novartis agreed to acquire Pikavation Therapeutics, Synnovation’s subsidiary, for up to $3 billion including $2 billion upfront to secure SNV4818, a pan‑mutant selective PI3Kα inhibitor in early clinical testing for HR+/HER2‑ metastatic breast cancer. Novartis said SNV4818 targets mutated PI3Kα while sparing wild‑type enzyme to improve tolerability and enable combinations with endocrine therapies. Synnovation will retain other R&D units and continue independent programs. Mutant‑selective PI3Kα inhibitors aim to limit on‑target toxicities that have hindered earlier compounds.
-
Pfizer, Valneva miss statistical bar on Lyme shot — plan to file anyway
Pfizer and Valneva reported Phase 3 data showing their Lyme disease vaccine reduced cases by roughly 70–73% but failed to meet the trial’s pre‑specified statistical threshold because fewer than expected infections occurred. Both companies said efficacy and safety signals were clinically meaningful and that they plan to seek regulatory approval despite the primary analysis miss. The result raises a regulatory debate over prespecified endpoints versus totality of evidence; regulators will assess the clinical relevance alongside statistical methodology.
-
Apogee posts long‑acting eczema wins — dosing every 3–6 months shows durability
Apogee Therapeutics released Phase 2 maintenance data for zumilokibart (APG‑777) showing durable skin and itch responses with dosing intervals of three and six months. Company‑reported endpoints included high rates of EASI‑75 maintenance at one year and a favorable safety profile versus current biologics. Analysts upgraded peak sales forecasts and flagged the compound as a potential competitor to Dupixent and Ebglyss if results replicate in larger trials. Maintenance dosing data support potential differentiation through dosing convenience and long‑interval regimens.
-
Sanofi pays $180M up front for Kali’s trispecific — big autoimmune bet
Sanofi licensed KT‑501, a trispecific T‑cell engager from Kali Therapeutics, in a deal that includes roughly $180 million in upfront and near‑term payments and more than $1 billion in milestones plus tiered royalties. Kali recently dosed the first patient in a Phase 1 trial for rheumatoid arthritis. The asset targets multiple B‑cell related pathways (CD19/BCMA/CD3) and represents Sanofi’s return to multispecific T‑cell engager strategies. Trispecifics combine several specificities in one molecule to broaden target engagement or safety tuning; partners often aim to accelerate clinical development and commercial scale through such alliances.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.